Related Experiment Videos

Focal adhesion kinase: a promising target for anticancer therapy

Nikolaos A Chatzizacharias1, Gregory P Kouraklis, Stamatios E Theocharis

  • 1National and Kapodistrian University of Athens, Department of Forensic Medicine and Toxicology, Medical School, 75, Mikras Asias Street, Goudi, Athens, GR11527, Greece.

Expert Opinion on Therapeutic Targets
|October 3, 2007
PubMed

Insights

Targeting focal adhesion kinase (FAK), a key protein tyrosine kinase, shows promise in cancer therapy. Inhibiting FAK can reduce malignant traits and enhance cancer cell death, alone or with treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Focal adhesion kinase (FAK) is a protein tyrosine kinase crucial for integrin signaling and basic cellular functions.
  • In cancer cells, elevated FAK expression and signaling promote malignancy and treatment resistance.
  • FAK plays a significant role in cancer progression and therapeutic outcomes.

Purpose of the Study:

  • To comprehensively review the therapeutic potential of targeting FAK in anticancer strategies.
  • To explore FAK's role in cancer cell phenotype and treatment resistance.
  • To summarize current data on FAK as an anticancer target.

Main Methods:

  • Review of existing scientific literature on FAK targeting in cancer.
  • Analysis of studies investigating FAK inhibition alone and in combination therapies.
  • Examination of data on gene-based suppression of FAK activity.

Main Results:

  • Direct FAK targeting inhibits cancer cell malignant phenotypes.
  • FAK inhibition increases cancer cell apoptosis, enhancing efficacy of chemotherapy, radiotherapy, and hormonal therapy.
  • Cancer drugs can modulate FAK signaling; gene-based suppression (e.g., PTEN, RRM1, mda-7) shows positive outcomes.

Conclusions:

  • Targeting FAK represents a promising strategy in anticancer therapy.
  • FAK inhibition offers potential for enhancing conventional cancer treatments.
  • Modulating FAK signaling, through direct drugs or gene therapy, is a viable approach for cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...